SeroELISA Chlamydia True IgM Assay

$445.00

The SeroELISA Chlamydia True IgM Assay is intended for the detection of specific IgM antibodies to Chlamydia in a single human serum sample by an Enzyme-Linked Immunosorbent Assay (ELISA). The Eagle Biosciences SeroELISA Chlamydia IgA Assay Kit is for Research Use Only and is not intended for diagnostic or therapeutic purposes.

SKU: 112-01 Categories: , ,

SeroELISA Chlamydia True IgM Assay

The SeroELISA Chlamydia True IgM Assay is For Research Use Only

Size: 1×96 wells
Sensitivity: Cut-Off Control
Incubation Time: 2 hours
Sample Type: Serum
Sample Size: 10 µL


Assay Principle

Human serum to be tested is brought into contact with the antigenic material coating the microtiter wells. Specific antibody, if present in the patient serum will bind to the attached antigen, a complex is formed and all the serum components are washed away in the wash phase. Horseradish peroxidase (HRP) conjugated anti-human IgM (chain specific) is added to the wells. If an antigen-antibody complex was formed in the previous step, the peroxidase conjugated antibody will bind to the antibody moiety of the complex. If no antigen-antibody complex was formed in the previous step, the conjugate is washed away in the wash phase. TMB-Substrate is added. A positive reaction is indicated by a blue to deep blue color which develops in the test wells following enzymatic reaction of the peroxidase moiety with peroxide and the chromogen reactant. After the enzymatic reaction is stopped by an acidic solution, the absorbance of the test wells is determined at 450nm by a spectrophotometer. The absorbance at 450nm is indicative of IgM anti-Chlamydia titer in patient serum specimens.


Cross Reaction
Hospitalized patients, infected with Neisseria gonorrhea, Staphylococcus aureus and Peptostreptococcus anaerobius, who were diagnosed by commercial serology kits, were also tested with the SeroELISA Chlamydia kit. There was no significant cross-reaction detected.


Related Products

SeroELISA Chlamydia IgG Assay
SeroELISA Chlamydia IgA Assay Kit
SeroCP RT C. pneumoniae IgM ELISA Assay Kit

Additional Information

Assay Background


Chlamydia is a gram-negative obligate intracellular bacteria that causes acute and chronic diseases in mammalian and avian species. The genus Chlamydia is comprised of four species: C.trachomatis, C.pneumoniae, C.psittaci and C. pecorum. C.trachomatis is divided into 15 serovars. Serovars A, B, Ba and C are agents of trachoma, the leading cause of preventable blindness endemic in third world countries. Serovars L1-L3 are the agents of lymphogranuloma venereum. Serovars D-K are the common cause of sexually transmitted genital infection worldwide: cervicitis, endometritis/ salpingitis in females and urethritis in both males and females. Endometritis/salpingitis can lead to tubal occlusion with a higher risk of extra uterine pregnancy and infertility. Genital infection may cause an acute and persistent infection occasionally without any clinical symptoms. Generally, these infections are treatable once they are diagnosed. However without any treatment the infection may progress to a severe chronic inflammation leading to infertility, ectopic pregnancy, induced abortion or premature delivery. Moreover, infants to infected mothers may be infected during birth, leading to conjunctivitis or pneumonia. C.pneumoniae is an important respiratory pathogen in humans and causes up to 10% of community-acquired pneumonia cases. It has been associated with acute respiratory diseases, pneumonia, asthma, bronchitis, pharyngitis, acute chest syndrome of sickle cell disease, coronary heart disease, and Guillain-Barre syndrome. C.psittaci infects a diverse range of host species from molluscs to birds to mammals and also causes severe pneumonia.

Serodiagnostic tests, which rely on specific immunologic markers, serve as a non-invasive diagnostic tool in identification of both distal and deep infections. It has been found that ANTI-Chlamydia IgM antibody is of diagnostic value in pneumonia caused by C. pneumoniae (TWAR) and C.psittaci. The serological pattern of Chlamydia IgM in chlamydial pneumonititis is as follows: antibodies are produced in the early stages of an infection, peak after 1-2 weeks and generally decline gradually to undetectable levels within 2-3 months. This pattern has been observed in 20-50% of infants born to mothers who were culture positive for Chlamydia trachomatis and/or demonstrated elevated levels of specific IgG and IgA antibodies to Chlamydia. These infants developed chlamydial pneumonitis during the first 6 months of life. Since IgM is present only in acute and/or recent disease, the Chlamydia IgM test requires only a single serum specimen and results can be reported in terms of presence or absence of immune IgM. High titers of immune IgG, which compete with immune IgM for the same antigenic sites, may produce false negative IgM results. Rheumatoid factor (Rf, autoimmune activity) causes false positive IgM results. Therefore, removal of IgG and Rf is an essential part of the IgM assay. SeroELISATM Chlamydia test employs the L2 serovar broadly reacting antigen of C. trachomatis. It will detect C. trachomatis, C. psittaci and C. pneumoniae (TWAR) antibodies.

Manual

Product Manual


Publications

References


  1. Yuan, Y., Zhang, Y. X., Watkins, N. G. and Caldwell, H.D. (1989). Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15 Chlamydia trachomatis Serovars. Infection and Immunity. 57:1040-1049. Copyright 1989, American Society for Microbiology.
  2. Treharne J. D. (1985). The community epidemiology of trachoma. Rev Infect Dis. 7:760-763.
  3. Piura, B., Sarov, I., Sarov, B., Kleinman, D., Chaim, W. and Insler, V. (1985). Serum IgG and IgA antibodies specific for Chlamydia trachomatis in salpingitis patients as determined by the immunoperoxidase assay. Eur. J. Epidemiol 1: 110-116.
  4. Wang, S.P., Grayston, J.T., Kuo, C.C., Alexander, E.R., and Holmes, K.K. (1977). SeroDiagnosis of Chlamydia trachomatis infection with the microimmunofluorescence test. In: Nongonoccolcal urethritis and related infection, D. Hobson and K.K. Holmes (Eds), P. American Society for Microbiology, Washington DC. p. 237-248.
  5. Thompson III S. E., and Dretler R. H. (1982). Epidemiology and Treatment of Chlamydial Infections in Pregnant Women and Infants. Review of Infectious Diseases 4:S747
  6. Saikku P., Mattila, K., Nieminen, M.S., Huttunen, J.K., Leinonen, M., Ekman, M.R., Makela, P.H., and Valtonen, V. (1988). Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infection. Lancet II: 983-986.
  7. Puolakkainen, M., Saikku, P., Leinonen, M., Nurminen, V., Vaananen, P. and Makela, P.H. (1984). Chlamydia Pneumonitis and its Serodiagnosis in Infants. J. Infect. Dis. 149:598-604.
  8. Grayson, J.G. (1989). Chlamydia pneumoniae, Strain TWAR. Chest 95:664-669.
  9. Gardner, P.S. Rapid Virus Diagnosis. In Voller, A., Bartlett, A. and Bidwell, D. (Eds). Immunoassays for the 80s, pp. 353-360 MTP Press Limited 1981.
  10. Chantler, S. and Diment, J.A. current Status of Specific IgM Antibody Assays. In Voller, A., Bartlett, A. and Bidwell, D. (Eds). Immunoassays for the 80s, pp. 417-430 MTP Press Limited 1981.
  11. Numazaki, K., Chiba, S., Yamanaka, T., Moroboshi, T., Aoki, K., Nakao, T. (1985). Detection of IgM Antibodies against Chlamydia trachomatis by Enzyme Linked Fluorescence Immunoassay. J.Clin. Pathol. 38:733-739.

Product Citations